Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Target Engagement of BMS-986147 in Healthy Subjects
NCT02293629Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986147 in autoimmune diseases (5 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of single oral dose of BMS-986147 and Safety and tolerability of multiple oral dose of BMS-986147. Started Oct 2014; status: completed.
02
Drugs
BMS-986147
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT02293629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293629.